System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Gloria Pessina is an expert in Hematology at INFN Sezione di Milano Bicocca (Italy). Gloria Pessina has authored 95 publications, the most recent in 2025. SLR score: 111 (community average: 125). How the SLR is computed.

LeadR Profile

Gloria Pessina INFN Sezione di Milano Bicocca Italy
111 ScienceLeadR Reputation 111

Unlock

Register Login
Network Map

Hematology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2012 - 2025
Source: PubMed

INFN Sezione di Milano Bicocca

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 95

Citations

Citations: 9 043 1st author: 0 Last author: 2 Unique author: 0

Main journals

Phys Rev Lett 51
Eur Phys J C Part Fields 20
Blood 3
Nature 3
Ann Oncol 2

Best Journals

Nature 3
Ann Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Half-Life and Precision Shape Measurement of the 2νββ Decay of ^{130}Te.
PMID 40929320 — research design, physics, nuclear matrix		Phys Rev Lett20250
Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation.
PMID 38471404 — prognosis, neoplasms, mastocytosis, systemic, chimera, frameshift mutation, receptor, platelet-derived growth factor beta		Cancer Genet20243
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
PMID 37231885 — hematology, risk, myelodysplastic syndromes, therapeutics, leukemia, myeloid, acute		Eur J Haematol20232
Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
PMID 37232844 — antibody formation, sars-cov-2, disease outbreaks, vaccines, incidence, neoplasms, treatment failure, vaccination, covid-19, immunity, therapeutics, severe acute respiratory syndrome-related coronavirus, infections, breakthrough infections		Curr Oncol20235
Characterization of a kg-scale archaeological lead-based PbWO cryogenic detector for the RES-NOVA experiment.
PMID 36731392		Appl Radiat Isot20235

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS